40 In patients with T2DM, the SURPASS-2 trial compared tirzepatide with semaglutide 1 mg (both as add-on therapies to metformin) and found tirzepatide was either noninferior or superior at all doses (5 mg, 10 mg 15 mg), for both HbA 1c reduction and weight loss at 40 weeks
Subjects with diabetes were excluded
We estimated the total annual cost to be $4,857,458.20 ($1,598.90 3,038 IPPS hospitals) (Table 158)
doi: 10.1038/s41598-018-23697-5 58 van DieckJTeufelDPJaulentAMFernandez-FernandezMRRutherfordTJWyslouch-CieszynskaAet al
Our program will improve your overall health while reducing your risk of diabetes, high blood pressure, heart disease and arthritis
NMN at 250 mg/day for 12 weeks significantly increased NAD+ metabolites and improved physical performance (Yoshino et al., 2021)